We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Photoacoustic Technology May Revolutionize Cancer Research

By LabMedica International staff writers
Posted on 13 Apr 2011
Innovative technology that combines the sensitivity of optical imaging with the resolution and depth penetration of high-frequency ultrasound will enable researchers to study cancer in its earliest stages of progression and evaluate tumor growth and the effect that potential drugs have on that growth.

The VisualSonics Inc. More...
(Toronto, Canada) Vevo LAZR uses a laser to shoot pulses of light through the skin into tissue and cells beneath the surface. The absorbed laser energy is then converted into heat, producing an ultrasonic emission, which can be captured and turned into images using a specially adapted high frequency ultrasonic probe. VisualSonics is a wholly owned subsidiary of SonoSite Inc. (Seattle, WA, USA).

The key to this novel approach is the capability of a wide range of biological materials to absorb laser light. Specific tissue components including oxyhemoglobin, deoxyhemoglobin, melanin, and lipids all absorb laser energy, which is then converted into heat that produces an ultrasonic emission that can be captured and turned into images using a specially adapted high frequency ultrasonic probe.

Applications for the Vevo LAZR system range from lymph node imaging to the study of hemoglobin and oxygen saturation and the targeted imaging of tumor biomarkers. In addition to cancer biology, this innovative technology will benefit other areas of life science research such as diabetes, neurosciences, and developmental and reproductive biology.

"The Vevo LAZR photoacoustics system is a breakthrough in vivo imaging technology,” said Anil Amlani president and CEO of VisualSonics. "Advancements featured in this product will enable oncology researchers to accelerate their research into understanding of the inner workings of the cancerous cell and the host tissue in which it resides. The ability to conduct this microscopic level research in a living organism, noninvasively and in real time will help our customers to turn groundbreaking science into lifesaving care, at an even greater speed.”

"We believe that the Vevo LAZR system will have a strong impact on the discovery of new cancer therapies, more efficient testing of therapies with never-before-seen insights into cancer, and quantified measures of cancer progression, viewed from inside the tumor,” said Kevin M. Goodwin, president and CEO of SonoSite. "With the launch of Vevo LAZR technology, we continue to meet our commitment to our customers by providing imaging technologies needed to further tomorrow's research today.”

Related Links:

VisualSonics Inc.
SonoSite Inc.



New
Gold Member
Automatic CLIA Analyzer
Shine i9000
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.